Risk Factors and Opportunities for Prevention of Early-Onset Neonatal Sepsis: A Multicenter Case-Control Study

Background. Early-onset group B streptococcal (GBS) prevention efforts are based on targeted use of intrapartum antibiotic prophylaxis (IAP); applicability of these prevention efforts to infections caused by other organisms is not clear. Methods. Multicenter surveillance during 1995 to 1996 for culture-confirmed, early-onset sepsis in an aggregate of 52 406 births; matched case-control study of risk factors for GBS and other sepsis. Results. Early-onset disease occurred in 188 infants (3.5 cases per 1000 live births). GBS (1.4 cases per 1000 births) andEscherichia coli (0.6 cases per 1000 births) caused most infections. GBS sepsis less often occurred in preterm deliveries compared with other sepsis. Compared with gestation-matched controls without documented sepsis, GBS disease was associated with intrapartum fever (matched OR, 4.1; CI, 1.2–13.4) and frequent vaginal exams (matched OR, 2.9; CI, 1.1–8.0). An obstetric risk factor—preterm delivery, intrapartum fever, or membrane rupture ≥18 hours—was found in 49% of GBS cases and 79% of other sepsis. IAP had an adjusted efficacy of 68.2% against any early-onset sepsis. Ampicillin resistance was evident in 69% of E coliinfections. No deaths occurred among susceptible E coliinfections, whereas 41% of ampicillin-resistant E coliinfections were fatal. Ninety-one percent of infants who developed ampicillin-resistant E coli infections were preterm, and 59% of these infants were born to mothers who had received IAP. Conclusions. Either prenatal GBS screening or a risk-based strategy could potentially prevent a substantial portion of GBS cases. Sepsis caused by other organisms is more often a disease of prematurity. IAP seemed efficacious against early-onset sepsis. However, the severity of ampicillin-resistant E colisepsis and its occurrence after maternal antibiotics suggest caution regarding use of ampicillin instead of penicillin for GBS prophylaxis.

[1]  T. Asrat,et al.  Potential consequences of widespread antepartal use of ampicillin. , 1998, American journal of obstetrics and gynecology.

[2]  E. Hodnett,et al.  International multicenter term PROM study: evaluation of predictors of neonatal infection in infants born to patients with premature rupture of membranes at term. Premature Rupture of the Membranes. , 1998, American journal of obstetrics and gynecology.

[3]  R. Holman,et al.  Decline in Sepsis-associated Neonatal and Infant Deaths in the United States, 1979 Through 1994 , 1998, Pediatrics.

[4]  J. Miranda,et al.  Timing of Intrapartum Ampicillin and Prevention of Vertical Transmission of Group B Streptococcus , 1998, Obstetrics and gynecology.

[5]  N. F. Jacobs,et al.  Neonatal early-onset Escherichia coli disease. The effect of intrapartum ampicillin. , 1998, Archives of pediatrics & adolescent medicine.

[6]  Adams Willie J. Anderson Patsy A. Hall Amy K. Henion Myr Trosclair Adoption of hospital policies for prevention of perinatal group B streptococcal disease--United States, 1997. , 1998, MMWR. Morbidity and mortality weekly report.

[7]  Z. Bhutta,et al.  Early-Onset Neonatal Sepsis in Pakistan: A Case Control Study of Risk Factors in a Birth Cohort , 1997, American journal of perinatology.

[8]  G. Thurnau,et al.  Antibiotic Therapy for Reduction of Infant Morbidity After Preterm Premature Rupture of the Membranes: A Randomized Controlled Trial , 1997 .

[9]  L. Wright,et al.  Revised guidelines for prevention of early-onset group B streptococcal (GBS) infection. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. , 1997, Pediatrics.

[10]  Decreasing incidence of perinatal group B streptococcal disease--United States, 1993-1995. , 1997, Canada communicable disease report = Releve des maladies transmissibles au Canada.

[11]  G. Thurnau,et al.  Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. , 1997, JAMA.

[12]  A. Schuchat,et al.  The Accuracy of Late Antenatal Screening Cultures in Predicting Genital Group B Streptococcal Colonization at Delivery , 1996, Obstetrics and gynecology.

[13]  A. Schuchat,et al.  Prevention of perinatal group B streptococcal disease : a public health perspective , 1996 .

[14]  D. Schendel,et al.  Prevalence of selected developmental disabilities in children 3-10 years of age: the Metropolitan Atlanta Developmental Disabilities Surveillance Program, 1991. , 1996, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[15]  B. Frentzen,et al.  Peripartum infection associated with vaginal group B streptococcal colonization , 1994, Obstetrics and gynecology.

[16]  A. Schuchat,et al.  Multistate case-control study of maternal risk factors for neonatal group B streptococcal disease. The Active Surveillance Study Group. , 1994, The Pediatric infectious disease journal.

[17]  A. Schuchat,et al.  Epidemiology of group B streptococcal disease. Risk factors, prevention strategies, and vaccine development. , 1994, Epidemiologic reviews.

[18]  R. Gibbs,et al.  Adverse perinatal outcome and resistant Enterobacteriaceae after antibiotic usage for premature rupture of the membranes and group B streptococcus carriage , 1993, Obstetrics and gynecology.

[19]  S. Garland,et al.  Group B Streptococcus (GBS) and Neonatal Infections: The Case for Intrapartum Chemoprophylaxis , 1991, The Australian & New Zealand journal of obstetrics & gynaecology.

[20]  A. Schuchat,et al.  Population-based risk factors for neonatal group B streptococcal disease: results of a cohort study in metropolitan Atlanta. , 1990, The Journal of infectious diseases.

[21]  K. Boyer,et al.  Prevention of early‐onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis , 1986, The New England journal of medicine.